Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03816332
Title Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)

basal cell carcinoma

skin squamous cell carcinoma

Merkel cell carcinoma

Advanced Solid Tumor



Ipilimumab + Nivolumab + Prednisone + Tacrolimus

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.